Abstract
Background Kidney transplantation is the best option for the treatment of end-stage kidney disease (ESKD). Acute rejection (AR) episodes are a major determinant of renal allograft survival. Cellular senescence in the pathogenesis of allograft failure. Herein, we aimed to explore hub cellular senescence-related gene in AR after kidney transplantation.
Methods The data used in this study was obtained from the Gene Expression Omnibus database. The hub cellular senescence-related gene was identified using WGCNA and three machine learning algorithms. The function information was analyzed using the GO and KEGG enrichment analysis. The correlation between hub gene and immune cells was calculated using ssGSEA algorithm and Pearson’s correlation analysis.
Results A total of 31 cellular senescence-related genes were differentially expressed in the AR and stable groups. Among which, 19 genes were correlated with onset of AR after kidney transplantation. After utilizing the three machine learning algorithms, IFNG was identified as the hub cellular senescence-related gene. IFNG was highly expressed in AR samples, and it could better distinguish between stable individuals and AR patients after kidney transplantation. Moreover, the expression of IFNG was closely correlated with immune cell infiltration and function. IFNG expression was associated with multiple drugs. Finally, we found that IFNG was high expressed in kidney tissues of AR in allogeneic kidney transplant mice
Conclusions Our study revealed that cellular senescence-related gene IFNG might be a potential biomarker AR after kidney transplantation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Science and technology project program of Liaoning Province (2022020774-JH2/1015).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
